<?xml version="1.0" encoding="UTF-8"?>
<doi_batch version="5.4.0" xmlns="http://www.crossref.org/schema/5.4.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xsi:schemaLocation="http://www.crossref.org/schema/5.4.0 http://www.crossref.org/schema/deposit/crossref5.4.0.xsd">
<head>
  <doi_batch_id>53a7bb081a034df5681-14bc</doi_batch_id>
  <timestamp>20260825055842000</timestamp>
  <depositor>
    <depositor_name>chitu:chitu</depositor_name>
    <email_address>chitkarauniversitypublications@chitkara.edu.in</email_address>
  </depositor>
  <registrant>WEB-FORM</registrant>
</head>
<body>
  <journal>
    <journal_metadata>
  <full_title>Journal of Pharmaceutical Technology, Research and Management</full_title>
  <abbrev_title>JPTRM</abbrev_title>
  <issn media_type='print'>23212217</issn>
  <issn media_type='electronic'>23212225</issn>
  <doi_data>
  <doi>10.15415/jptrm</doi>
  <resource>https://jptrm.chitkara.edu.in/</resource>
  </doi_data>
</journal_metadata>
<journal_issue>
  <publication_date media_type='print'>
    <month>08</month>
    <day>17</day>
    <year>2026</year>
  </publication_date>
  <publication_date media_type='online'>
    <month>08</month>
    <day>17</day>
    <year>2026</year>
  </publication_date>
  <journal_volume>
    <volume>14</volume>
  </journal_volume>
  <issue>1</issue>
  <doi_data>
  <doi>10.15415/jptrm.2026.141</doi>
  <resource>https://jptrm.chitkara.edu.in/2026/volume-14-and-issue-1/</resource>
  </doi_data>
</journal_issue><!-- ============== -->
<journal_article publication_type='full_text'>
  <titles>
  <title>Pharmacophore-Based 3D-QSAR and Molecular Docking Studies of Novel 1,3,4-Thiadiazole Derivatives as Potential α-Glucosidase Inhibitors</title>
  <original_language_title>Pharmacophore-Based 3D-QSAR and Molecular Docking Studies of Novel 1,3,4-Thiadiazole Derivatives as Potential α-Glucosidase Inhibitors</original_language_title>
  </titles>
  <contributors>
    <person_name sequence='first' contributor_role='author'>
     <given_name>Debarshi</given_name>
      <surname>Mondal</surname>
<affiliations><institution><institution_name>Department of Pharmaceutical Chemistry, SWIFT School of Pharmacy, Ghaggar Sarai, Rajpura, Patiala, PIN-140401, Punjab, India.</institution_name></institution></affiliations>      <ORCID>https://orcid.org/0009-0006-6392-0009</ORCID>
    </person_name>
    <person_name sequence='additional' contributor_role='author'>
      <given_name>Priya</given_name>
      <surname>Devi</surname>
<affiliations><institution><institution_name>Department of Pharmaceutical Chemistry, University School of Pharmaceutical Sciences, Rayat Bahra Professional University,  Bohan, Nangal Shahidan, Hoshiarpur, PIN-146023, Punjab, India.</institution_name></institution></affiliations>      <ORCID>https://orcid.org/0009-0003-9576-0837</ORCID>
    </person_name>
    <person_name sequence='additional' contributor_role='author'>
      <given_name>Shalini</given_name>
      <surname>Sharma</surname>
<affiliations><institution><institution_name>Department of Pharmaceutics, SWIFT School of Pharmacy, Ghaggar Sarai, Rajpura, Patiala, PIN-140401, Punjab, India.</institution_name></institution></affiliations>    </person_name>
    <person_name sequence='additional' contributor_role='author'>
      <given_name>Harmel Singh</given_name>
      <surname>Chahal</surname>
<affiliations><institution><institution_name>Department of Pharmacology, SWIFT School of Pharmacy, Ghaggar Sarai, Rajpura, Patiala, PIN-140401, Punjab, India.</institution_name></institution></affiliations>    </person_name>
  </contributors>
  <jats:abstract xml:lang='en'>
    <jats:p>Background: Metabolic Disorder Type 2 Diabetes mellitus (T2DM) is a chronic disease that involves hyperglycemia due to insulin resistance and impaired insulin secretion. α-glucosidase inhibition has been proven to be a therapeutic approach for controlling postprandial hyperglycemia and is a well-established treatment for T2DM. 1,3,4-thiadiazole is a promising pharmacophore among heterocyclic scaffolds due to its broad range of biological activities, including α-glucosidase inhibition.

Purpose: The present study was designed to identify and optimize novel 1,3,4-thiadiazole derivatives as α-glucosidase inhibitors using an integrated computer-aided drug design (CADD) approach that includes pharmacophore modeling, 3D-QSAR, molecular docking, optimization of R-groups, and ADMET prediction.

Methods: A total of 34 reported 1,3,4-thiadiazole derivatives were analyzed to build an optimal pharmacophore model (AADHR₃) as well as atom-based (R² = 0.799, Q² = 0.822) and Gaussian field-based 3D-QSAR models (R² = 0.967, Q² = 0.682). The structurally optimized lead compounds were then identified by molecular docking, R-group optimization, and ADMET prediction.

Results: The analysis of the contour map showed that bulky hydrophobic groups in the R₁ position and electron-withdrawing groups in the R₂ position were beneficial for enhancing α-glucosidase inhibitory activity. The docking score of five compounds was comparable or better than that of acarbose (−6.260 kcal/mol), with the best score being compound 25 (−6.686 kcal/mol). The designed derivatives (DM1 (−7.625 kcal/mol), DM2 (−7.418 kcal/mol), and DM3 (−7.284 kcal/mol)) showed better binding abilities and favorable interactions with Arg281, Asp282, Asp404, Asp518, Asp616, His674, and Phe525, in addition to promising ADMET properties.

Conclusion: Pharmacophore analysis, 3D-QSAR, molecular docking, SAR, and ADMET studies indicated that the 1,3,4-thiadiazole scaffold could be a promising template for designing potent α-glucosidase inhibitors. The optimized derivatives, especially DM1–DM3, are good lead candidates for further development into therapeutic drugs for T2DM.</jats:p>
  </jats:abstract>
  <publication_date media_type='print'>
    <month>8</month>
    <day>17</day>
    <year>2026</year>
  </publication_date>
  <publication_date media_type='online'>
    <month>8</month>
    <day>17</day>
    <year>2026</year>
  </publication_date>
  <pages>
  <first_page>21</first_page>
  <last_page>48</last_page>
  </pages>
  <doi_data>
  <doi>10.15415/jptrm.2026.141002</doi>
  <resource>https://jptrm.chitkara.edu.in/2026/pharmacophore-based-3d-qsar-and-molecular-docking-studies-of-novel-134-thiadiazole-derivatives-as-potential-%ce%b1-glucosidase-inhibitors/</resource>
  </doi_data>
</journal_article>
  </journal>
</body>
</doi_batch>
